Amal Therapeutics raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds

Geneva/Berlin/Ingelheim/Bonn, 20th February 2014. Amal Therapeutics SA, a Swiss and German-­based company focusing on the development of therapeutic cancer vaccines, announced today that it has closed its seed financing round. The funds will be used to consolidate the cell-­penetrating peptide based technology platform and progress the first vaccine candidate up to pre-­clinical development. The investment round was led by Boehringer Ingelheim Venture Fund (BIVF), joined by the High-­Tech Gründerfonds (HTGF). The company also announced that it appointed Dr. Knut Elbers, Director and Investment Manager of the Boehringer Ingelheim Venture Fund to its board of directors.

View PDF